In fact, consolidation durvalumab treatment following cCRT significantly prolonged progression-free survival and OS in locally advanced NSCLC regardless of baseline PD-L1 status (either for TPS < 25 or for TPS ≥ 25).3,4 In the present study, the majority of patients showed an increase in TPS after cCRT (Fig. 1). This evidence concerns the gene CD274 and non-small cell lung carcinoma.